RayKnowChina Research Map
Shortlist

ShantouShantou University Medical College

Shantou University Medical College hospitals

汕头大学医学院附属医院

Listed for 15 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shantou University Medical College hospitals

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌8 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌66 papers led2 open trials led
  3. Hepatocellular carcinoma肝细胞癌25 papers led
  4. Stomach cancer胃癌26 papers led
  5. Hepatoblastoma肝母细胞瘤0 papers led
  6. Osteosarcoma骨肉瘤9 papers led
  7. Beta thalassaemiaβ 地中海贫血3 papers led
  8. Haemophilia A血友病 A0 papers led
  9. Biliary atresia胆道闭锁0 papers led
  10. Hepatic echinococcosis肝包虫病1 paper led
  11. Idiopathic pulmonary fibrosis特发性肺纤维化2 papers led
  12. Lymphangioleiomyomatosis肺淋巴管平滑肌瘤病1 paper led
  13. Amyotrophic lateral sclerosis肌萎缩侧索硬化症1 paper led
  14. IgA nephropathyIgA 肾病2 papers led
  15. Osteogenesis imperfecta成骨不全症0 papers led

Not listed for: Retinoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Anti-NMDA receptor encephalitis, Takayasu arteritis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 8 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
8
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
5
led by another institution
Papers led per year
2021: 3320212022: 0020222023: 1120232024: 1120242025: 112025

1 hospital in Shantou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07311772

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 16 listed hospitals as study sitesBeijing, Changsha, Changzhou, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shanghai, Shantou, Wuzhou, Zhuhai

  2. Recruiting
    Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and Immunotherapy
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328841

    Age 18 years to 70 years (registered criteria)

    Lead sponsor is not a listed hospital; 10 listed hospitals as study sitesChangsha, Guangzhou, Nanning, Shantou, Wuhan, Wuzhou, Zhongshan, Zhuhai

  3. Recruiting
    40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal Carcinoma
    Phase
    Phase 3
    Started
    2025-11
    Registry
    NCT07328854

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 14 listed hospitals as study sitesChangsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Kunming, Nanning, Shantou, Wuzhou, Zhongshan, Zhuhai

  4. Recruiting
    Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response
    Phase
    Phase 3
    Started
    2024-03
    Registry
    NCT06239727

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 21 listed hospitals as study sitesChangsha, Chengdu, Chongqing, Dongguan, Foshan, Fuzhou, Guangzhou, Guiyang, Haikou, Hangzhou, Nanchang, Nanjing, Nanning, Shantou, Tianjin, Wuhan, Xi'an, Xiamen, Zhanjiang

  5. Recruiting
    GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
    Phase
    Phase 2
    Started
    2024-06
    Registry
    NCT06455410

    Age 18 years to 65 years (registered criteria)

    Led by Sun Yat-sen Memorial Hospital; 7 listed hospitals as study sitesFoshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueRecurrent / metastatic diseaseSide effects & quality of life
Departments in papersRadiation oncologyENT / head & neck surgery
Papers it led8
  1. Adiponectin Receptor 1-vascular endothelial growth factor axis mediates resistance to epidermal growth factor receptor-targeted therapy in nasopharyngeal carcinoma.2026Anti-cancer drugs
  2. Nasal irrigation reduces radiation-induced rhinosinusitis in nasopharyngeal carcinoma treated with volumetric modulated arc therapy.2026Journal of stomatology, oral and maxillofacial surgery
  3. Comparing Flaps and Artificial Dermis for Skull Base Osteoradionecrosis Repair in Nasopharyngeal Carcinoma.2025The Laryngoscope
  4. A contrast-enhanced CT radiomics-based model to identify candidates for deintensified chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma patients.2024European radiology
  5. CPVL suppresses metastasis of nasopharyngeal carcinoma through inhibiting epithelial-mesenchymal transition.2023Journal of cancer research and clinical oncologyFree full text
  6. Autoantibody Signatures as a Biomarker Panel for the Detection of Nasopharyngeal Carcinoma.2021Archives of medical research
  7. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority2021Cancer medicineRCTFree full text
  8. Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high‑throughput omics (Review).2021International journal of oncologyFree full text
All its trials on ClinicalTrials.gov, any status12
  1. Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal CancerCompletedNCT05564286Lead sponsorPhase 3Start 2021-07
  2. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral LiquidRecruitingNCT07311772Study sitePhase 3Start 2025-12
  3. Reduced-dose Versus Conventional-dose Intensity-modulated Radiation Therapy for Locally Advanced Nasopharyngeal Carcinoma With Remission After Induction Chemotherapy and ImmunotherapyRecruitingNCT07328841Study sitePhase 3Start 2025-11
  4. 40.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaRecruitingNCT07328854Study sitePhase 3Start 2025-11
  5. Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment ResponseRecruitingNCT06239727Study sitePhase 3Start 2024-03
  6. GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal CarcinomaRecruitingNCT06455410Study sitePhase 2Start 2024-06
  7. Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.Active, not recruitingNCT07201337Study sitePhase 3Start 2025-11
  8. A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT05126719Study sitePhase 2Start 2023-04
  9. A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal CarcinomaActive, not recruitingNCT04974398Study sitePhase 3Start 2021-08
  10. Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)CompletedNCT03924986Study sitePhase 3Start 2019-03
  11. The Efficacy and Safety Study of TORIPALIMAB INJECTION Combined With Chemotherapy for Nasophapyngeal CancerCompletedNCT03581786Study sitePhase 3Start 2018-10
  12. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
More papers found outside PubMed (not counted)9
  1. 669MO Long term overall survival follow-up of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma2025Annals of Oncologyarticle
  2. Abstract CT011: Penpulimab versus placebo in combination with chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: A global, multicenter, randomized, double-blind, phase 3 trial (AK105-304)2025Cancer Researchconference-abstract
  3. Four-year overall survival follow-up and dynamic EBV titer analysis of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (r/m NPC).2024Journal of Clinical Oncologyconference-abstract
  4. 860MO MRG003: A novel EGFR-targeted antibody-drug conjugant (ADC) for recurrent/metastatic nasopharyngeal carcinoma2023Annals of Oncologyarticle
  5. Final overall survival analysis of JUPITER-02: A phase 3 study of toripalimab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2023Journal of Clinical Oncologyconference-abstract
  6. A Radiomics-Based Model to Identify Candidates for De-Intensified Treatment in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Abstract CT226: Final progression-free survival analysis of JUPITER-02, a randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal ca2022Cancer Researchconference-abstract
  8. 909P A phase II study of the anti-programmed cell death-1 (PD-1) antibody penpulimab in patients with metastatic nasopharyngeal carcinoma (NPC) who had progressed after two or more lines of chemotherapy: Updated results2021Annals of Oncologyarticle
  9. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 66 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 2.3%.

Papers led
66
2021–2025
Trials led
3
any status, ClinicalTrials.gov
Open trials led
2
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 9920212022: 121220222023: 171720232024: 131320242025: 14142025

2 hospitals in Shantou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

Open trials with this hospital 5

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2025-12
    Registry
    NCT07339488

    Age 18 years to 75 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  2. Recruiting
    Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma
    Phase
    Phase 1
    Started
    2023-08
    Registry
    NCT05984342

    Age 18 years to 70 years (registered criteria)

    Led by Shantou University Medical College hospitalsShantou

  3. Recruiting
    SKB500 Combinations in Patients With Esophageal Squamous Cell Carcinoma
    Phase
    Phase 2
    Started
    2026-08
    Registry
    NCT07700667

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 21 listed hospitals as study sitesChangchun, Chengdu, Chongqing, Fuzhou, Harbin, Kunming, Luoyang, Nanchang, Nanjing, Nanning, Shantou, Shenyang, Shijiazhuang, Shiyan, Taiyuan, Tianjin, Xi'an, Zhengzhou

  4. Recruiting
    A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
    Phase
    Phase 3
    Started
    2025-03
    Registry
    NCT06644781

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 28 listed hospitals as study sitesAnyang, Beijing, Changchun, Chengdu, Fuzhou, Hangzhou, Harbin, Hefei, Jinan, Jining, Linyi, Luoyang, Nanning, Shantou, Shenyang, Tianjin, Wuhan, Xiamen, Xinxiang, Yangzhou, Zhengzhou

  5. Recruiting
    Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC
    Phase
    Phase 2
    Started
    2024-10
    Registry
    NCT06637163

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 4 listed hospitals as study sitesHangzhou, Shanghai, Shantou, Shenyang, Tianjin

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesMolecular markers & genomicsImaging & AINeoadjuvant & combined treatment
Departments in papersPathology / laboratory medicineRadiation oncologyMedical oncologyRadiology / nuclear medicine
Papers it led66
  1. Exploring solute carriers as biomarkers and therapeutic targets in esophageal squamous cell carcinoma.2026International journal of cancer
  2. Interplay and cooperation between GLI2 and master transcription factors promote progression of esophageal squamous cell carcinoma.2025American journal of human geneticsFree full text
  3. Machine learning technique-based four-autoantibody test for early detection of esophageal squamous cell carcinoma: a multicenter, retrospective study with a nested case-control study.2025BMC medicineFree full text
  4. Serum multiomics prediction of prognosis and adverse reactions to concurrent chemoradiotherapy in patients with esophageal cancer.2025British journal of cancerFree full text
  5. Prognostic Value of Deep Learning-Extracted Tumor-Infiltrating Lymphocytes in Esophageal Cancer: A Multicenter Retrospective Cohort Study.2025Cancer medicineFree full text
  6. Decoding epigenetic and transcriptional landscapes: DNA methylome-transcriptome integration reveals novel drivers in 4NQO-Induced esophageal squamous cell carcinoma mouse model.2025Clinical epigeneticsFree full text
  7. Increased IgG4 expression within tertiary lymphoid structures of esophageal cancer and implications for prognosis.2025Frontiers in immunologyFree full text
  8. Comprehensive analysis based on the ubiquitination- and deubiquitylation-related genes reveals the function of NEURL3 in esophageal squamous cell carcinoma.2025Frontiers in immunologyFree full text
  9. CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma.2025Journal of nanobiotechnologyFree full text
  10. Rho GAPase protein 1 (RACGAP1) affects the proliferation and metastasis of esophageal squamous cell carcinoma cells by regulating signaling pathways: Thermal infrared medical image inspection.2025Journal of thermal biology
  11. Nuclear ANLN regulates transcription initiation related Pol II clustering and target gene expression.2025Nature communicationsFree full text
  12. Transcriptomics-based analysis of key genes and potential mechanism and therapeutic agents in cadmium-induced esophageal squamous cell carcinoma progression.2025Scientific reportsFree full text
  13. Esophageal cancer trends in the US from 1992 to 2019 with projections to 2044 using SEER data.2025Scientific reportsFree full text
  14. Blood trace elements in association with esophageal squamous cell carcinoma risk, aggressiveness and prognosis in a high incidence region of China.2025Scientific reportsFree full text
  15. Lympho-myeloid aggregate-infiltrating CD20+ B cells display a double-negative phenotype and correlate with poor prognosis in esophageal squamous cell carcinoma.2025Translational research : the journal of laboratory and clinical medicine
  16. Secreted proteins encoded by super enhancer-driven genes could be promising biomarkers for early detection of esophageal squamous cell carcinoma.2024Biomedical journalFree full text
  17. Oncologic Outcome of Patients With Pathologic T0 Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  18. CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression.2024Cancer letters
  19. Construction and validation of classification models for predicting the response to concurrent chemo-radiotherapy of patients with esophageal squamous cell carcinoma based on multi-omics data.2024Clinics and research in hepatology and gastroenterology
  20. EZH2 elicits CD8+ T-cell desert in esophageal squamous cell carcinoma via suppressing CXCL9 and dendritic cells.2024Communications biologyFree full text
  21. First-Line Tislelizumab for Advanced or Metastatic Esophageal Squamous Cell Carcinoma:A Cost-Effectiveness Analysis.2024Expert review of pharmacoeconomics & outcomes research
  22. Efficacy of the induced pluripotent stem cell derived and engineered CD276-targeted CAR-NK cells against human esophageal squamous cell carcinoma.2024Frontiers in immunologyFree full text
  23. Discovery and validation of combined biomarkers for the diagnosis of esophageal intraepithelial neoplasia and esophageal squamous cell carcinoma.2024Journal of proteomics
  24. Early Diagnostic Markers for Esophageal Squamous Cell Carcinoma: Copy Number Alteration Gene Identification and cfDNA Detection.2024Laboratory investigation; a journal of technical methods and pathology
  25. NMR and MS reveal characteristic metabolome atlas and optimize esophageal squamous cell carcinoma early detection.2024Nature communicationsFree full text
  26. Serine/threonine-protein kinase D2-mediated phosphorylation of DSG2 threonine 730 promotes esophageal squamous cell carcinoma progression.2024The Journal of pathology
  27. KAT8/SIRT7-mediated Fascin-K41 acetylation/deacetylation regulates tumor metastasis in esophageal squamous cell carcinoma.2024The Journal of pathology
  28. Nomogram based on pretreatment hepatic and renal function indicators for survival prediction of locally advanced esophageal squamous cell carcinoma with treatment of neoadjuvant chemoradiotherapy plus surgery.2024Updates in surgery
  29. Development and Validation of a New Staging System for Esophageal Squamous Cell Carcinoma Patients Based on Combined Pathological TNM, Radiomics, and Proteomics.2023Annals of surgical oncology
  30. ASO Author Reflections: A Multiomic Novel Staging System for Esophageal Squamous Cell Carcinoma Patients.2023Annals of surgical oncology
  31. Relationship between esophageal squamous cell carcinoma risk and alcohol-related ALDH2 and ADH1B polymorphisms: Evidence from a meta-analysis and Mendelian randomization analysis.2023Cancer medicineFree full text
  32. circSSPO boosts growth of esophageal squamous cell carcinoma through upregulation of micrRNA-6820-5p-mediated KLK8 and PKD1 expression.2023Cell biology and toxicology
  33. Targeting USP10 induces degradation of oncogenic ANLN in esophageal squamous cell carcinoma.2023Cell death and differentiationFree full text
  34. Associations of trace element levels in paired serum, whole blood, and tissue: an example of esophageal squamous cell carcinoma.2023Environmental science and pollution research international
  35. Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China.2023Expert review of pharmacoeconomics & outcomes research
  36. Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma.2023Frontiers in immunologyFree full text
  37. Comprehensive analysis of cuproptosis genes and cuproptosis-related genes as prognosis factors in esophageal squamous cell carcinoma.2023Genomics
  38. Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma.2023Immunotherapy
  39. Different Expression Pattern of G Protein-Coupled Estrogen Receptor GPER1 in Esophageal Squamous Cell Carcinoma and Adenocarcinoma.2023International journal of molecular sciencesFree full text
  40. Acetyl-CoA Acetyltransferase 2 Confers Radioresistance by Inhibiting Ferroptosis in Esophageal Squamous Cell Carcinoma.2023International journal of radiation oncology, biology, physics
  41. Spatial analysis of stromal signatures identifies invasive front carcinoma-associated fibroblasts as suppressors of anti-tumor immune response in esophageal cancer.2023Journal of experimental & clinical cancer research : CRFree full text
  42. The Preoperative Neutrophil to Lymphocyte Ratio Predicts Survival in Patients with Esophageal Squamous Cell Carcinoma: a Propensity Score Matching Analysis.2023Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  43. CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma.2023Journal of translational medicineFree full text
  44. Prenylated PALM2 Promotes the Migration of Esophageal Squamous Cell Carcinoma Cells Through Activating Ezrin.2023Molecular & cellular proteomics : MCPFree full text
  45. A protein complex of LCN2, LOXL2 and MMP9 facilitates tumour metastasis in oesophageal cancer.2023Molecular oncologyFree full text
  46. Serum insulin-like growth factor binding protein-3 as a potential biomarker for diagnosis and prognosis of oesophageal squamous cell carcinoma.2022Annals of medicineFree full text
  47. TRIP13 Induces Nedaplatin Resistance in Esophageal Squamous Cell Carcinoma by Enhancing Repair of DNA Damage and Inhibiting Apoptosis.2022BioMed research internationalFree full text
  48. Role of Cell-Cell Junctions in Oesophageal Squamous Cell Carcinoma.2022BiomoleculesFree full text
  49. Serum DSG2 as a potential biomarker for diagnosis of esophageal squamous cell carcinoma and esophagogastric junction adenocarcinoma.2022Bioscience reportsFree full text
  50. Fascin lysine 471 acetylation cooperates with serine 39 phosphorylation to inhibit actin-bundling activity and tumor metastasis in esophageal squamous cell carcinoma.2022Cancer communications (London, England)Free full text
  51. Blocking STAT3 signaling augments MEK/ERK inhibitor efficacy in esophageal squamous cell carcinoma.2022Cell death & diseaseFree full text
  52. Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More.2022Frontiers in public healthFree full text
  53. Esophageal Squamous Cancer from 4NQO-Induced Mice Model: CNV Alterations.2022International journal of molecular sciencesFree full text
  54. Potential Chemotherapeutic Effect of Selenium for Improved Canceration of Esophageal Cancer.2022International journal of molecular sciencesFree full text
  55. PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p.2022Journal of experimental & clinical cancer research : CRFree full text
  56. Anti-tumour effects of a macrolide analog F806 in oesophageal squamous cell carcinoma cells by targeting and promoting GLUT1 autolysosomal degradation.2022The FEBS journal
  57. Surgical resection for esophageal adenosquamous carcinoma: an analysis of 56 cases.2022World journal of surgical oncologyFree full text
  58. Promotion of rs3746804 (p. L267P) polymorphism to intracellular SLC52A3a trafficking and riboflavin transportation in esophageal cancer cells.2021Amino acids
  59. P300/CBP-associated factor (PCAF)-mediated acetylation of Fascin at lysine 471 inhibits its actin-bundling activity and tumor metastasis in esophageal cancer.2021Cancer communications (London, England)Free full text
  60. STAT3β disrupted mitochondrial electron transport chain enhances chemosensitivity by inducing pyroptosis in esophageal squamous cell carcinoma.2021Cancer letters
  61. Identification and Validation of Esophageal Squamous Cell Carcinoma Targets for Fluorescence Molecular Endoscopy.2021International journal of molecular sciencesFree full text
  62. Systematic Proteome and Lysine Succinylome Analysis Reveals Enhanced Cell Migration by Hyposuccinylation in Esophageal Squamous Cell Carcinoma.2021Molecular & cellular proteomics : MCPFree full text
  63. The miR-19b-3p-MAP2K3-STAT3 feedback loop regulates cell proliferation and invasion in esophageal squamous cell carcinoma.2021Molecular oncologyFree full text
  64. Integrated single-cell transcriptome analysis reveals heterogeneity of esophageal squamous cell carcinoma microenvironment.2021Nature communicationsFree full text
  65. CircDUSP16 Contributes to Cell Development in Esophageal Squamous Cell Carcinoma by Regulating miR-497-5p/TKTL1 Axis.2021The Journal of surgical research
  66. linc01305 promotes metastasis and proliferation of esophageal squamous cell carcinoma through interacting with IGF2BP2 and IGF2BP3 to stabilize HTR3A mRNA.2021The international journal of biochemistry & cell biology
All its trials on ClinicalTrials.gov, any status19
  1. Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell CarcinomaRecruitingNCT05984342Lead sponsorPhase 1Start 2023-08
  2. Intestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable Esophageal Squamous Cell CarcinomaRecruitingNCT07339488Lead (inferred)Phase 2Start 2025-12
  3. Study of Simultaneous Modulated Accelerated Radiation Therapy Concurrent With Chemotherapy to Treat Esophageal CancerCompletedNCT01670409Lead (inferred)Phase 2Start 2012-08
  4. SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingNCT07700667Study sitePhase 2Start 2026-08
  5. A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)RecruitingNCT06644781Study sitePhase 3Start 2025-03
  6. Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCCRecruitingNCT06637163Study sitePhase 2Start 2024-10
  7. Study To Investigate the Efficacy and Safety of Sitravatinib in Combination With Tislelizumab in Participants With Esophageal Squamous Cell CarcinomaTerminatedNCT05461794Study sitePhase 2Start 2022-10
  8. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  9. Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell CarcinomaActive, not recruitingNCT04848753Study sitePhase 3Start 2021-05
  10. A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent ChemoradiotherapyCompletedNCT04543617Study sitePhase 3Start 2020-09
  11. A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal CarcinomaCompletedNCT04540211Study sitePhase 3Start 2020-10
  12. Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal LesionsStatus unknownNCT04170257Study siteN/AStart 2019-10
  13. A Study of CS1001 in Subjects With Esophageal Squamous Cell CarcinomaCompletedNCT04187352Study sitePhase 3Start 2019-12
  14. A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03430843Study sitePhase 3Start 2018-01
  15. A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell CarcinomaCompletedNCT03783442Study sitePhase 3Start 2018-12
  16. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  17. A Phase III Study of Nimotuzumab Plus Concurrent Chemoradiotherapy in Loco-regional Esophageal Squamous Cell CarcinomaStatus unknownNCT02409186Study sitePhase 3Start 2015-03
  18. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  19. Phase III Study of Neo-adjuvant Chemoradiotherapy Followed by Surgery for Squamous Cell Esophageal CancerStatus unknownNCT01216527Study sitePhase 3Start 2007-06
More papers found outside PubMed (not counted)11
  1. Long-Term Outcomes of Dose Escalation in Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multicenter, Randomized Phase III Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow2024Journal of Clinical Oncologyconference-abstract
  3. 1514P Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs placebo (PBO) + chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update2023Annals of Oncologyarticle
  4. Abstract CT076: Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis2023Cancer Researchconference-abstract
  5. 70O Randomized, global, phase III study of tislelizumab (TIS) + chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup2022Annals of Oncologyarticle
  6. ASO Visual Abstract: Combined Mean Corpuscular Hemoglobin, Fibrinogen, and Albumin (MF-A) Is a Novel Prognostic Marker in Patients with Resectable Esophageal Squamous Cell Carcinoma2022Annals of Surgical Oncologyarticle
  7. Additional file 1 of PABPC1-induced stabilization of IFI27 mRNA promotes angiogenesis and malignant progression in esophageal squamous cell carcinoma through exosomal miRNA-21-5p2022Figsharedataset
  8. LBA-1 RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)2022Annals of Oncologyarticle
  9. Relationship between esophageal squamous cell carcinoma risk and ALDH2 and ADH1B polymorphisms:Evidence from a Meta-Analysis2022Zenodo (CERN European Organization for Nuclear Research)article
  10. Corrigendum: TRPC1 Inhibits Cell Proliferation/Invasion and Is Predictive of a Better Prognosis of Esophageal Squamous Cell Carcinoma2021Frontiers in Oncologyerratum
  11. Decreased Average Albumin-to-Globulin Ratio During Radiotherapy Worsens the Prognosis of Esophageal Squamous Cell Carcinoma: Implications for Nutritional Management2021journal of nutritional oncologyarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 25 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
25
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 2220222023: 6620232024: 6620242025: 772025

1 hospital in Shantou for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImmunotherapy & targeted drugsHepatitis B & cirrhosis
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyRadiology / nuclear medicine

Over half of these papers are lab or animal studies.

Papers it led25
  1. Crippled Hepatocarcinogenesis Inhibition of Quercetin in Glycolysis Pathway with Hepatic Farnesoid X Receptor Deficiency.2025Current pharmaceutical design
  2. Exosomal ETV4 Derived From M2 Macrophages Induces Growth, Glycolysis and Stemness in Hepatocellular Carcinoma by UpRegulating SULT2B1 Expression.2025Liver international : official journal of the International Association for the Study of the Liver
  3. Integrated multiomics analysis highlights the immunosuppressive role of granulin precursor positive macrophages in hepatocellular carcinoma.2025PeerJFree full text
  4. Unsupervised Clustering Subtype Analysis and Prognostic Risk Model of Cuproptosis-Related Genes for Liver Cancer.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  5. AFB1 consolidates HBV harm to induce liver injury and carcinogenic risk by inactivating FTCD-AS1-PXR-MASP1 axis.2025Toxicology
  6. Human endogenous retrovirus ERVK3-1 characterizes a metabolically active and immunosuppressive subtype of liver cancer.2025Virology journalFree full text
  7. The Intrinsic Innate Immunity of Hepatocytes Suppresses HBV Replication and Is Antagonized by HBx.2025VirusesFree full text
  8. Comparative analysis of the performance of hepatobiliary agents in depicting MRI features of microvascular infiltration in hepatocellular carcinoma.2024Abdominal radiology (New York)
  9. Camrelizumab plus rivoceranib compared sorafenib as first-line therapeutic options for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024BMJ openFree full text
  10. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.2024Frontiers in public healthFree full text
  11. Exosomal IGFBP2 derived from highly metastatic promotes hepatocellular carcinoma metastasis by inducing epithelial mesenchymal transition.2024Gene
  12. MRTO4 Enhances Glycolysis to Facilitate HCC Progression by Inhibiting ALDOB.2024Medical science monitor : international medical journal of experimental and clinical researchFree full text
  13. Improvement of rat hepatocellular carcinoma model induced by diethylnitrosamine.2024Tissue & cell
  14. Expression Patterns of HOX Gene Family Defines Tumor Microenvironment and Immunotherapy in Hepatocellular Carcinoma.2023Applied biochemistry and biotechnology
  15. Disulfidptosis-related signatures for prognostic and immunotherapy reactivity evaluation in hepatocellular carcinoma.2023European journal of medical researchFree full text
  16. Circ_0031242 regulates the functional properties of hepatocellular carcinoma cells through the miR-944/MAD2L1 axis.2023Histology and histopathology
  17. The relationship between the efficacy of thermal ablation and inflammatory response and immune status in early hepatocellular carcinoma and the progress of postoperative adjuvant therapy.2023International immunopharmacology
  18. C-Terminal Truncated HBx Facilitates Oncogenesis by Modulating Cell Cycle and Glucose Metabolism in FXR-Deficient Hepatocellular Carcinoma.2023International journal of molecular sciencesFree full text
  19. Hollow Mesoporous Silica Nanoparticles for Dual Chemo-starvation Therapy of Hepatocellular Carcinoma.2023Pharmaceutical research
  20. The Prognostic and Immunotherapeutic Significance of AHSA1 in Pan-Cancer, and Its Relationship With the Proliferation and Metastasis of Hepatocellular Carcinoma.2022Frontiers in immunologyFree full text
  21. Purine-Induced IFN-γ Promotes Uric Acid Production by Upregulating Xanthine Oxidoreductase Expression.2022Frontiers in immunologyFree full text
  22. A novel prognostic signature based on four glycolysis-related genes predicts survival and clinical risk of hepatocellular carcinoma.2021Journal of clinical laboratory analysisFree full text
  23. Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish.2021Journal of experimental & clinical cancer research : CRFree full text
  24. Combination of curcumin with N-n-butyl haloperidol iodide inhibits hepatocellular carcinoma malignant proliferation by downregulating enhancer of zeste homolog 2 (EZH2) - lncRNA H19 to silence Wnt/β-catenin signaling.2021Phytomedicine : international journal of phytotherapy and phytopharmacology
  25. Partial abrogation of FXR-KNG1 signaling by carboxyl-terminal truncated HBx-C30 in hepatitis B virus-associated hepatocellular carcinoma.2021Virus research
Chinese-language papers (not in the count)1
  1. [Clinical application of bipolar tweezers-clamp for hepatic parenchymal transection].2022Zhonghua wai ke za zhi [Chinese journal of surgery]
All its trials on ClinicalTrials.gov, any status2
  1. Single-arm, Open-label Clinical Study of SZ003 in the Treatment of Advanced Hepatocellular CarcinomaTerminatedNCT05845502Lead sponsorN/AStart 2021-07
  2. A Study to Evaluate SHR-1210 in Subjects With Advanced HCCCompletedNCT02989922Study sitePhase 2Start 2016-11

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 26 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.3%.

Papers led
26
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
3
led by another institution
Papers led per year
2021: 5520212022: 2220222023: 7720232024: 8820242025: 442025

1 hospital in Shantou for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  2. Recruiting
    Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in China
    Phase
    Not given
    Started
    2025-02
    Registry
    NCT06846996

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 32 listed hospitals as study sitesBeijing, Changchun, Fuzhou, Guangzhou, Haikou, Hangzhou, Nanjing, Shanghai, Shantou, Shenyang, Taiyuan, Taizhou, Tianjin, Xuzhou, Zhengzhou

  3. Recruiting
    OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap Method
    Phase
    N/A
    Started
    2022-09
    Registry
    NCT05450835

    Age 18 years to 75 years (registered criteria)

    Led by Nanfang Hospital; 7 listed hospitals as study sitesChangchun, Changsha, Guangzhou, Shantou, Shenyang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseImmunotherapy & targeted drugsImaging & AI
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Medical oncologyENT / head & neck surgery
Papers it led26
  1. Development and validation of the antibody-dependent cellular phagocytosis-based signature: A prognostic risk model of gastric cancer.2025Advances in clinical and experimental medicine : official organ Wroclaw Medical University
  2. Cost-effectiveness analysis of cadonilimab plus chemotherapy as a first-line treatment option in HER-2-negative advanced gastric cancer.2025Frontiers in public healthFree full text
  3. Programmed cell death 1 inhibitor combined with chemotherapy compared to chemotherapy alone as first-line treatment in advanced gastric cancer patients: A real-world study.2025International immunopharmacology
  4. Sugemalimab plus chemotherapy versus chemotherapy for advanced gastric cancer in China: a cost-effectiveness analysis.2025Scientific reportsFree full text
  5. Expression and prognostic value of APOBEC2 in gastric adenocarcinoma and its association with tumor-infiltrating immune cells.2024BMC cancerFree full text
  6. Genomic characteristics and evolution of Multicentric Esophageal and gastric Cardiac Cancer.2024Biology directFree full text
  7. Pembrolizumab combined with chemotherapy versus placebo combined with chemotherapy for HER2-negative advanced gastric cancer in China: a cost-effectiveness analysis.2024Expert review of pharmacoeconomics & outcomes research
  8. Identification and characterization of CLEC11A and its derived immune signature in gastric cancer.2024Frontiers in immunologyFree full text
  9. Genome-wide DNA methylation and transcriptomic patterns of precancerous gastric cardia lesions.2024Journal of the National Cancer Institute
  10. OLFM4 promotes the progression of intestinal metaplasia through activation of the MYH9/GSK3β/β-catenin pathway.2024Molecular cancerFree full text
  11. Machine learning based intratumor heterogeneity signature for predicting prognosis and immunotherapy benefit in stomach adenocarcinoma.2024Scientific reportsFree full text
  12. Combined detection of serum EFNA1 and MMP13 as diagnostic biomarker for gastric cancer.2024Scientific reportsFree full text
  13. Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol.2023BMC gastroenterologyFree full text
  14. Immune checkpoint inhibitors and cellular immunotherapy for advanced gastric, gastroesophageal cancer: a long pathway.2023Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  15. Grid2 interacting protein is a potential biomarker related to immune infiltration in colorectal cancer.2023European journal of medical researchFree full text
  16. Genome-wide DNA methylation profiling of gastric cardia cancer.2023Journal of gastroenterology and hepatology
  17. Establishment and characterization of two Epstein-Barr virus-positive gastric cancer cell lines with epitheliotropic M81 strain undergoing distinct viral and altered cellular expression profiles.2023Journal of medical virology
  18. Epstein-Barr virus-encoded miR-BART11-3p modulates the DUSP6-MAPK axis to promote gastric cancer cell proliferation and metastasis.2023Journal of virologyFree full text
  19. The diagnostic value of serum insulin-like growth factor binding protein 7 in gastric cancer.2023PeerJFree full text
  20. A novel 8-genome instability-associated lncRNAs signature predicting prognosis and drug sensitivity in gastric cancer.2022International journal of immunopathology and pharmacologyFree full text
  21. Circular RNA circ_0006089 promotes the progression of gastric cancer by regulating the miR-143-3p/PTBP3 axis and PI3K/AKT signaling pathway.2022Journal of digestive diseases
  22. Clinical correlations and prognostic value of Nudix hydroxylase 10 in patients with gastric cancer.2021BioengineeredFree full text
  23. Early B-cell factors involve in the tumorigenesis and predict the overall survival of gastric cancer.2021Bioscience reportsFree full text
  24. Serum CYR61 as a potential biomarker for the diagnosis of esophagogastric junction tumor.2021Bioscience reportsFree full text
  25. Lymph Node Ratio Is an Independent Prognostic Factor for Patients with Siewert Type II Adenocarcinoma of Esophagogastric Junction: Results from a 10-Year Follow-up Study.2021Journal of gastrointestinal cancer
  26. Accumulation of Nicotinamide N-Methyltransferase (NNMT) in Cancer-associated Fibroblasts: A Potential Prognostic and Predictive Biomarker for Gastric Carcinoma.2021The journal of histochemistry and cytochemistry : official journal of the Histochemistry SocietyFree full text
Chinese-language papers (not in the count)1
  1. [Application of laparoscopic and open gastrectomy in enhanced recovery after surgery for gastric cancer: analysis of data from multiple centers in China].2021Nan fang yi ke da xue xue bao = Journal of Southern Medical UniversityFree full text
All its trials on ClinicalTrials.gov, any status11
  1. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  2. Real-world Effectiveness and Safety of Trastuzumab Deruxtecan in Patients With Locally Advanced or Metastatic HER2-positive Gastric or Gastroesophageal Junction Adenocarcinoma in ChinaRecruitingNCT06846996Study siteStart 2025-02
  3. OGT-assisted Overlap Esophagojejunostomy Versus Traditional Overlap MethodRecruitingNCT05450835Study siteN/AStart 2022-09
  4. A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015)Active, not recruitingNCT06356311Study sitePhase 3Start 2024-05
  5. Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) OverexpressionCompletedNCT05052801Study sitePhase 3Start 2022-03
  6. Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.TerminatedNCT05111626Study sitePhase 3Start 2022-03
  7. A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-OverexpressionStatus unknownNCT04714190Study sitePhase 3Start 2021-03
  8. A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction CancerCompletedNCT03694522Study sitePhase 2Start 2018-09
  9. Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric CancerCompletedNCT03427814Study sitePhase 2Start 2018-07
  10. The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCCStatus unknownNCT02915432Study sitePhase 1/Phase 2Start 2016-12
  11. Compare S-1 Plus Oxaliplatin to S-1 as Adjuvant Chemotherapy After D2 Resection in Patients With Gastric CancerStatus unknownNCT01795027Study sitePhase 3Start 2011-09

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led no English-language PubMed papers on hepatoblastoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shantou for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 9 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 4420232024: 3320242025: 002025

2 hospitals in Shantou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Over half of these papers are lab or animal studies.

Papers it led9
  1. Circ_0002669 promotes osteosarcoma tumorigenesis through directly binding to MYCBP and sponging miR-889-3p.2024Biology direct
  2. CircPVT1 promotes migration and invasion by regulating miR-490-5p/HAVCR2 axis in osteosarcoma cells.2024Journal of cellular and molecular medicine
  3. A tumor suppressor protein encoded by circKEAP1 inhibits osteosarcoma cell stemness and metastasis by promoting vimentin proteasome degradation and activating anti-tumor immunity.2024Journal of experimental & clinical cancer research : CR
  4. LncRNA WAC-AS1 promotes osteosarcoma Metastasis and stemness by sponging miR-5047 to upregulate SOX2.2023Biology direct
  5. The Influence of MDR1 Expression Regulated by miR-138 through TRPS1 Signaling Pathway on Multidrug Resistance of Osteosarcoma and Formation of Bacterial Infection Biofilm.2023Cellular and molecular biology (Noisy-le-Grand, France)
  6. PITX1 suppresses osteosarcoma metastasis through exosomal LINC00662-mediated M2 macrophage polarization.2023Clinical & experimental metastasis
  7. RAMP1 as a novel prognostic biomarker in pan-cancer and osteosarcoma.2023PloS one
  8. Hsa_circ_0001017 promotes cell proliferation, migration and invasion in osteosarcoma by sponging miR-145-5p.2022Journal of orthopaedic surgery and research
  9. Oncogenic gene TRIM10 confers resistance to cisplatin in osteosarcoma cells and activates the NF-κB signaling pathway.2021Cell biology international
Earlier papers (2016–2020)3
  1. Cadmium chloride enhances cisplatin sensitivity in osteosarcoma cells by reducing FOXM1 expression.2020Oncology reports
  2. Phage display-derived oligopeptide-functionalized probes for in vivo specific photoacoustic imaging of osteosarcoma.2017Nanomedicine : nanotechnology, biology, and medicine
  3. MiR-19a regulates the cell growth and apoptosis of osteosarcoma stem cells by targeting PTEN.2017Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Beta thalassaemia

β 地中海贫血

Led 3 of the 312 English-language PubMed papers on beta thalassaemia with an author in mainland China, 2021–2025: 1.0%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 2220242025: 002025

2 hospitals in Shantou for beta thalassaemia133 hospitals in China for beta thalassaemia

No open trial on beta thalassaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led no English-language PubMed papers on haemophilia A in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shantou for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersClinical trials / research unit
Chinese-language papers (not in the count)1
  1. Systemic lupus erythematosus with acquired hemophilia A: A case report and literature review.2023Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences

Run the PubMed searchClinicalTrials.gov

Other diseases

Biliary atresia

胆道闭锁

Led no English-language PubMed papers on biliary atresia in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shantou for biliary atresia31 hospitals in China for biliary atresia

No open trial on biliary atresia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Hepatic echinococcosis

肝包虫病

Led 1 of the 152 English-language PubMed papers on hepatic echinococcosis with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

1 hospital in Shantou for hepatic echinococcosis44 hospitals in China for hepatic echinococcosis

No open trial on hepatic echinococcosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersClinical trials / research unit

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 2 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 0020242025: 002025

1 hospital in Shantou for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Lymphangioleiomyomatosis

肺淋巴管平滑肌瘤病

Led 1 of the 45 English-language PubMed papers on lymphangioleiomyomatosis with an author in mainland China, 2021–2025: 2.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

1 hospital in Shantou for lymphangioleiomyomatosis27 hospitals in China for lymphangioleiomyomatosis

No open trial on lymphangioleiomyomatosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Amyotrophic lateral sclerosis

肌萎缩侧索硬化症

Led 1 of the 779 English-language PubMed papers on amyotrophic lateral sclerosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Shantou for amyotrophic lateral sclerosis182 hospitals in China for amyotrophic lateral sclerosis

No open trial on amyotrophic lateral sclerosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicine

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 2 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 0.3%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

3 hospitals in Shantou for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNephrology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led no English-language PubMed papers on osteogenesis imperfecta in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Shantou for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

汕头大学医学院附属医院

Shantou University Medical College hospitals

汕头

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Shantou University Medical College; Cancer Hospital of Shantou University Medical College; First Affiliated Hospital of Shantou University Medical College; Medical College of Shantou University; Affiliated Cancer Hospital of Shantou University Medical College; Second Affiliated Hospital of Shantou University Medical College; Shantou University; 汕头大学医学院附属肿瘤医院

Suggest a correctionDownload the data